Stock Comparison

NVO vs UNH

Novo Nordisk A/S vs UnitedHealth Group Inc

The Verdict

NVO takes this one.

Winner

NVO

Novo Nordisk A/S

1.4

out of 10

Distressed

UNH

UnitedHealth Group Inc

0.3

out of 10

Distressed

Head-to-Head

$1.1T

Market Cap

$276.2B

10.7

P/E Ratio

22.9

33.1%

Profit Margin

2.7%

61.1%

Return on Equity

12.5%

0.7

Debt-to-Equity

0.0

Moderate

Overall Risk

Moderate-High

1.4

DVR Score

0.3

The Deep Dive

NVO1.4/10

Novo Nordisk (NVO) remains a formidable pharmaceutical giant, leading in diabetes and obesity care with its dominant GLP-1 franchise. The company is financially robust, boasts significant proprietary assets, and has a strategic vision for new therapeutic applications and AI integration. Recent FDA approvals for Wegovy HD and oral Wegovy are positive developments, enhancing its product portfolio. H...

Full NVO Analysis

UNH0.3/10

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...

Full UNH Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.